Bavarian Nordic Receives U.S. and EU Approvals of its Fill and Finish Vaccine Manufacturing Facility

COPENHAGEN, Denmark, July 27, 2022 – Bavarian Nordic A/S (OMX:BAVA) announced today that the Company has received approvals from the U.S. and EU regulatory authorities to manufacture JYNNEOS^®/IMVANEX^® smallpox and monkeypox vaccine at the Company’s fill and finish facility in Denmark. With the approvals of the final drug production – the process by which the vaccine is formulated and filled into vials – the Company is now allowed to deliver drug product manufactured at its own site to the U.S. and EU market.